Genentech Director Andrew “Andy” Chan, the new Visiting Professor of the InFLAMES Flagship, will arrive in Turku on 26 May.
Dr. Andrew Chan is Senior Vice President of Research-Biology at Genentech, Inc where he oversees biological research across all therapeutic areas including oncology, immunology, neuroscience, infectious diseases and regenerative medicine.
He is a leader in biotherapeutics discovery and development and integrates lessons learned about disease pathogenesis and mechanisms of therapy. Chan’s research focuses on how our immune systems protect us against foreign pathogens and yet cause autoimmune and inflammatory diseases. Chan is also co-inventor of ocrelizumab (Ocrevus™), the first B-cell directed therapy approved by the FDA for treatment of both relapsing and progressive forms of multiple sclerosis.
In Turku, Chan will meet researchers and students from the InFLAMES flagship. During his visit, he will also hold two seminars open to the public:
27 May, 12:00-13:00 career lecture Serendipity and embracing the unknown, Arje Schein Lecture Hall, Dentalia.
28 May, 12:00-13:00, science lecture 50 years of antibody technology: past, present and future, Lauren 2 Lecture Hall, Medisiina D.
If you are interested in meeting Andy Chan, please contact InFLAMES Research Coordinator Sampo Koivunen, (sampo.koivunen@utu.fi).
